Name | Title | Contact Details |
---|
Shamrock Marketing De, Inc. is a Chino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humanized Solutions is a Concord, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LifeSign is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The IlluminOss System utilizes a light-curable polymer, contained within an expandable balloon catheter to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in the EU under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Flare Capital Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.